An Indian perspective on the use of fluticasone/formoterol in asthma and chronic obstructive pulmonary disease patients
Despite rapidly evolving health-care systems, India continues to have a high disease burden for asthma and chronic obstructive pulmonary disease (COPD). The Asia-Pacific Asthma Insights and Management survey clearly revealed that asthma management remains very poor with worst clinical outcomes in In...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Jaypee Brothers Medical Publisher
2021-01-01
|
| Series: | Indian Journal of Respiratory Care |
| Subjects: | |
| Online Access: | http://www.ijrc.in/article.asp?issn=2277-9019;year=2021;volume=10;issue=2;spage=196;epage=200;aulast=Sharma |
| _version_ | 1797694280130625536 |
|---|---|
| author | Rahul Sharma Zafar Ahmad Iqbal Hemant Kalra Abhinav Guliani Anil K Singh Akshay Budhraja Gaurav Jain Bharat Mehrotra Loveleen Mangla Avi Kumar Vinay Purohit Monika Chinda |
| author_facet | Rahul Sharma Zafar Ahmad Iqbal Hemant Kalra Abhinav Guliani Anil K Singh Akshay Budhraja Gaurav Jain Bharat Mehrotra Loveleen Mangla Avi Kumar Vinay Purohit Monika Chinda |
| author_sort | Rahul Sharma |
| collection | DOAJ |
| description | Despite rapidly evolving health-care systems, India continues to have a high disease burden for asthma and chronic obstructive pulmonary disease (COPD). The Asia-Pacific Asthma Insights and Management survey clearly revealed that asthma management remains very poor with worst clinical outcomes in India. Potent inhaled corticosteroids (ICS) and quick onset of long-acting beta2-agonist (LABA) are considered to be optimal dual therapy for management of asthma and COPD. Fluticasone's long-term action against inflammation and formoterol's rapid long-term bronchodilator action are vital clinical attributes for optimal asthma maintenance treatment. In an 8- and 12-week trial, dual therapy of fluticasone and formoterol (FF) reported lung function improvements and better control of asthma than its monotherapy. A large clinical study revealed mild adverse events of dual FF than other dual ICS-LABA combinations. Recent pooled analysis of asthma showed that fluticasone shares a lower risk of pneumonia in asthma. Dual ICS-LABA therapies are preferred in COPD individuals with history of exacerbations. Numerous clinical studies showed significant efficacy, dose adjustments/switching, and safety outcomes with dual FF therapy in asthma and COPD. Dual FF inhaler therapy ensures highly potent anti-inflammatory activity and sustained bronchodilation, thus making this a preferred combination in terms of efficacy, safety, and patient adherence in asthma and COPD. This present review focuses on the combination therapy of formoterol and fluticasone for managing asthma and COPD. |
| first_indexed | 2024-03-12T02:54:39Z |
| format | Article |
| id | doaj.art-ecd7ca99438e454184f3b61ef961b212 |
| institution | Directory Open Access Journal |
| issn | 2277-9019 2321-4899 |
| language | English |
| last_indexed | 2024-03-12T02:54:39Z |
| publishDate | 2021-01-01 |
| publisher | Jaypee Brothers Medical Publisher |
| record_format | Article |
| series | Indian Journal of Respiratory Care |
| spelling | doaj.art-ecd7ca99438e454184f3b61ef961b2122023-09-03T15:24:08ZengJaypee Brothers Medical PublisherIndian Journal of Respiratory Care2277-90192321-48992021-01-0110219620010.4103/ijrc.ijrc_134_20An Indian perspective on the use of fluticasone/formoterol in asthma and chronic obstructive pulmonary disease patientsRahul SharmaZafar Ahmad IqbalHemant KalraAbhinav GulianiAnil K SinghAkshay BudhrajaGaurav JainBharat MehrotraLoveleen ManglaAvi KumarVinay PurohitMonika ChindaDespite rapidly evolving health-care systems, India continues to have a high disease burden for asthma and chronic obstructive pulmonary disease (COPD). The Asia-Pacific Asthma Insights and Management survey clearly revealed that asthma management remains very poor with worst clinical outcomes in India. Potent inhaled corticosteroids (ICS) and quick onset of long-acting beta2-agonist (LABA) are considered to be optimal dual therapy for management of asthma and COPD. Fluticasone's long-term action against inflammation and formoterol's rapid long-term bronchodilator action are vital clinical attributes for optimal asthma maintenance treatment. In an 8- and 12-week trial, dual therapy of fluticasone and formoterol (FF) reported lung function improvements and better control of asthma than its monotherapy. A large clinical study revealed mild adverse events of dual FF than other dual ICS-LABA combinations. Recent pooled analysis of asthma showed that fluticasone shares a lower risk of pneumonia in asthma. Dual ICS-LABA therapies are preferred in COPD individuals with history of exacerbations. Numerous clinical studies showed significant efficacy, dose adjustments/switching, and safety outcomes with dual FF therapy in asthma and COPD. Dual FF inhaler therapy ensures highly potent anti-inflammatory activity and sustained bronchodilation, thus making this a preferred combination in terms of efficacy, safety, and patient adherence in asthma and COPD. This present review focuses on the combination therapy of formoterol and fluticasone for managing asthma and COPD.http://www.ijrc.in/article.asp?issn=2277-9019;year=2021;volume=10;issue=2;spage=196;epage=200;aulast=Sharmaasthmachronic obstructive pulmonary diseasedual fluticasone and formoteroldual inhaled corticosteroid–long-acting beta2-agonistinhaler |
| spellingShingle | Rahul Sharma Zafar Ahmad Iqbal Hemant Kalra Abhinav Guliani Anil K Singh Akshay Budhraja Gaurav Jain Bharat Mehrotra Loveleen Mangla Avi Kumar Vinay Purohit Monika Chinda An Indian perspective on the use of fluticasone/formoterol in asthma and chronic obstructive pulmonary disease patients Indian Journal of Respiratory Care asthma chronic obstructive pulmonary disease dual fluticasone and formoterol dual inhaled corticosteroid–long-acting beta2-agonist inhaler |
| title | An Indian perspective on the use of fluticasone/formoterol in asthma and chronic obstructive pulmonary disease patients |
| title_full | An Indian perspective on the use of fluticasone/formoterol in asthma and chronic obstructive pulmonary disease patients |
| title_fullStr | An Indian perspective on the use of fluticasone/formoterol in asthma and chronic obstructive pulmonary disease patients |
| title_full_unstemmed | An Indian perspective on the use of fluticasone/formoterol in asthma and chronic obstructive pulmonary disease patients |
| title_short | An Indian perspective on the use of fluticasone/formoterol in asthma and chronic obstructive pulmonary disease patients |
| title_sort | indian perspective on the use of fluticasone formoterol in asthma and chronic obstructive pulmonary disease patients |
| topic | asthma chronic obstructive pulmonary disease dual fluticasone and formoterol dual inhaled corticosteroid–long-acting beta2-agonist inhaler |
| url | http://www.ijrc.in/article.asp?issn=2277-9019;year=2021;volume=10;issue=2;spage=196;epage=200;aulast=Sharma |
| work_keys_str_mv | AT rahulsharma anindianperspectiveontheuseoffluticasoneformoterolinasthmaandchronicobstructivepulmonarydiseasepatients AT zafarahmadiqbal anindianperspectiveontheuseoffluticasoneformoterolinasthmaandchronicobstructivepulmonarydiseasepatients AT hemantkalra anindianperspectiveontheuseoffluticasoneformoterolinasthmaandchronicobstructivepulmonarydiseasepatients AT abhinavguliani anindianperspectiveontheuseoffluticasoneformoterolinasthmaandchronicobstructivepulmonarydiseasepatients AT anilksingh anindianperspectiveontheuseoffluticasoneformoterolinasthmaandchronicobstructivepulmonarydiseasepatients AT akshaybudhraja anindianperspectiveontheuseoffluticasoneformoterolinasthmaandchronicobstructivepulmonarydiseasepatients AT gauravjain anindianperspectiveontheuseoffluticasoneformoterolinasthmaandchronicobstructivepulmonarydiseasepatients AT bharatmehrotra anindianperspectiveontheuseoffluticasoneformoterolinasthmaandchronicobstructivepulmonarydiseasepatients AT loveleenmangla anindianperspectiveontheuseoffluticasoneformoterolinasthmaandchronicobstructivepulmonarydiseasepatients AT avikumar anindianperspectiveontheuseoffluticasoneformoterolinasthmaandchronicobstructivepulmonarydiseasepatients AT vinaypurohit anindianperspectiveontheuseoffluticasoneformoterolinasthmaandchronicobstructivepulmonarydiseasepatients AT monikachinda anindianperspectiveontheuseoffluticasoneformoterolinasthmaandchronicobstructivepulmonarydiseasepatients AT rahulsharma indianperspectiveontheuseoffluticasoneformoterolinasthmaandchronicobstructivepulmonarydiseasepatients AT zafarahmadiqbal indianperspectiveontheuseoffluticasoneformoterolinasthmaandchronicobstructivepulmonarydiseasepatients AT hemantkalra indianperspectiveontheuseoffluticasoneformoterolinasthmaandchronicobstructivepulmonarydiseasepatients AT abhinavguliani indianperspectiveontheuseoffluticasoneformoterolinasthmaandchronicobstructivepulmonarydiseasepatients AT anilksingh indianperspectiveontheuseoffluticasoneformoterolinasthmaandchronicobstructivepulmonarydiseasepatients AT akshaybudhraja indianperspectiveontheuseoffluticasoneformoterolinasthmaandchronicobstructivepulmonarydiseasepatients AT gauravjain indianperspectiveontheuseoffluticasoneformoterolinasthmaandchronicobstructivepulmonarydiseasepatients AT bharatmehrotra indianperspectiveontheuseoffluticasoneformoterolinasthmaandchronicobstructivepulmonarydiseasepatients AT loveleenmangla indianperspectiveontheuseoffluticasoneformoterolinasthmaandchronicobstructivepulmonarydiseasepatients AT avikumar indianperspectiveontheuseoffluticasoneformoterolinasthmaandchronicobstructivepulmonarydiseasepatients AT vinaypurohit indianperspectiveontheuseoffluticasoneformoterolinasthmaandchronicobstructivepulmonarydiseasepatients AT monikachinda indianperspectiveontheuseoffluticasoneformoterolinasthmaandchronicobstructivepulmonarydiseasepatients |